In mouse tumor models, NVP-CGM097, an MDM2 inhibitor, led to an elevation in the dendritic cell count, the proportion of T cells in tumors and tumor-draining lymph nodes, and the ratio of CD8 + T cells to regulatory T cells in tumors [49]. Here, CD8A is linked to neoplasm.